Ken Griffin Adicet Bio, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 13,300 shares of ACET stock, worth $16,093. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,300

Previous 1,700 682.35%

Holding current value

$16,093

Previous $3,000 933.33%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.76 - $3.45 $184,773 - $362,198	104,985 Added 78.8%	238,214 $559,000
Q4 2023 Feb 14, 2024	BUY	$1.11 - $1.89 $37,975 - $64,660	34,212 Added 34.55%	133,229 $251,000
Q3 2023 Nov 14, 2023	BUY	$1.37 - $3.4 $100,692 - $249,893	73,498 Added 288.01%	99,017 $135,000
Q2 2023 Aug 14, 2023	SELL	$2.13 - $7.13 $612,285 - $2.05 Million	-287,458 Reduced 91.85%	25,519 $62,000
Q1 2023 May 15, 2023	SELL	$5.52 - $9.23 $381,271 - $637,525	-69,071 Reduced 18.08%	312,977 $1.8 Million

Q4 2022 Feb 14, 2023	BUY	$7.72 - $21.27 $930,422 - $2.56 Million	120,521 Added 46.08%	382,048 $3.42 Million
Q3 2022 Nov 14, 2022	BUY	$13.43 - $18.74 $2.11 Million - $2.94 Million	156,986 Added 150.17%	261,527 $3.72 Million
Q2 2022 Aug 15, 2022	BUY	$10.26 - $20.81 $130,979 - $265,660	12,766 Added 13.91%	104,541 $1.53 Million
Q1 2022 May 16, 2022	BUY	$11.53 - $19.97 $624,084 - $1.08 Million	54,127 Added 143.77%	91,775 $1.83 Million
Q4 2021 Feb 14, 2022	BUY	$7.37 - $17.49 $67,995 - $161,362	9,226 Added 32.46%	37,648 $658,000
Q1 2021 May 17, 2021	BUY	$12.12 - $17.17 $344,474 - $488,005	28,422 New	28,422 $355,000

Others Institutions Holding ACET

# of Institutions

107

Shares Held

69.5M

Call Options Held

13.3K

Put Options Held

24.6K

View Full List

About Adicet Bio, Inc.

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $48.4M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

More about ACET

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account